Sartorius Stedim Biotech stock falls 1.58 percent and trails its yearly high

Veröffentlicht am: 26.09.2026 um 09:09 Uhr | Redaktionelle Verantwortung: Rafael Müller, Chefredakteur AD HOC NEWS

Barclays lifted its Sartorius Stedim Biotech stock target from EUR 210 to EUR 240 on September 7, 2026. The EUR 212.40 price stood 5.2 percent below its yearly high.

Fotorealistische Aufnahme einer sterilen Bioprozessanlage mit Einwegbeuteln und Bioreaktoren — Sartorius Stedim Biotech produziert sterile Einwegbeutel und Bioreaktoren für Biopharma-Hersteller weltweit, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech stock (ISIN FR0013154002) was last at EUR 212.40 on Euronext Paris on September 25, 2026 at 5:35 p.m. CEST, down 1.58 percent. That left the price 5.2 percent below its 52-week high of EUR 224.00.

Barclays raises its target

Barclays raised its price target from EUR 210 to EUR 240 and retained its Overweight rating, according to finanzen.net on September 7, 2026. Analyst James Gordon identified Sartorius Stedim Biotech as a favored life-science equipment name.

The EUR 240 target stands 13.0 percent above the September 25 price of EUR 212.40. The difference frames the central investor debate: Barclays expects an equipment-business recovery, while the stock's valuation depends on the company converting that recovery into earnings growth.

Trading range stays wide

The September 25 quotation compared with a prior-session close of EUR 215.80. During the session, the shares traded between EUR 212.20 and EUR 218.80, with volume of 89,707 shares.

The 52-week span of EUR 150.00 to EUR 224.00 remains broad. At EUR 212.40, the stock stood EUR 62.40 above the yearly low, while its market capitalization was EUR 20.7 billion as of September 25, 2026.

Margins support the outlook

First-half 2026 revenue reached EUR 1,527.0 million, while EBITDA totaled EUR 463.7 million and the EBITDA margin was 31.4 percent, as Ideal Investor reported. The same report cited annual targets of EUR 3,153.8 million in revenue and EUR 989.2 million in EBITDA.

Those targets imply an EBITDA margin of 31.4 percent, matching the first-half level. For investors, maintaining that profitability while revenue expands is the operational test behind the higher analyst target.

October report is next

Third-quarter results are scheduled for October 22, 2026, according to Boursorama. The report can show whether the first-half margin and annual targets remain aligned.

Stock remains below its high

Sartorius Stedim Biotech stock was last at EUR 212.40 on Euronext Paris on September 25, 2026 at 5:35 p.m. CEST. Its 1.58 percent decline left the shares below the EUR 224.00 yearly high but above the EUR 150.00 yearly low.